Solid Tumors

Gene therapy combined with radiation shows tumor shrinkage

Published in Gene Therapy Weekly, December 12th, 2002

GenVec, Inc., (GNVC) announced that final results from its phase Ib clinical trial of lead oncology product candidate, TNFerade, in patients with a variety of solid tumors was presented at the American Society of Clinical Oncology (ASCO) Molecular Therapeutics Symposium in San Diego, California.

The phase Ib clinical trials of TNFerade, principally designed to assess the safety of the product candidate, were conducted at four centers around the country and involved patients with a wide variety of cancers including cancer of the pancreas, breast, lung, head and neck, skin, colon, and rectum. TNFerade showed substantial activity against a broad range of tumor...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-12-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry